Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anticholinergics for overactive bladder: does subtype selectivity play a role?].

M C Michel1, M M Barendrecht, M Oelke

  • 1Abteilung Pharmakologie & Pharmakotherapie, Academisch Medisch Centrum, Universität, Meibergdreef 15, NL-1105 AZ Amsterdam, the Netherlands. m.c.michel@amc.uva.nl

Der Urologe. Ausg. A
|June 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of geriatric patients with benign prostatic hyperplasia].

Der Urologe. Ausg. A·2020
Same author

[Sophisticated surgical management of distinctive patients with benign prostatic hyperplasia (BPH)].

Der Urologe. Ausg. A·2020
Same author

[Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse : Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology].

Der Urologe. Ausg. A·2019
Same author

[Acute urinary retention in men: efficacy of alpha-blockers in catheter removal after urinary retention].

Der Urologe. Ausg. A·2019
Same author

[Diagnostic procedures and diagnostic strategy for lower urinary tract symptoms/benign prostatic hyperplasia : An overview].

Der Urologe. Ausg. A·2019
Same author

[Fake News BPH - what is really true!]

Der Urologe. Ausg. A·2019
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Anticholinergic drugs for overactive bladder target muscarinic receptors. While M(3) selectivity, like with darifenacin, may reduce side effects, clinical data on efficacy and tolerability compared to other agents remain limited.

Area of Science:

  • Pharmacology
  • Urology

Context:

  • Overactive bladder (OAB) is treated with anticholinergics that block muscarinic receptors.
  • Five muscarinic receptor subtypes (M1-M5) exist, with M3 receptors mediating desired therapeutic effects.

Purpose:

  • To evaluate the theoretical benefits and clinical evidence for M3-selective anticholinergics, such as darifenacin, in treating overactive bladder.
  • To compare the efficacy, tolerability, and side effect profiles of M3-selective agents against other anticholinergics.

Summary:

  • Anticholinergics for OAB target muscarinic receptors; M3 receptors are key for efficacy, while M1, M2, and M3 contribute to side effects.
  • Darifenacin, an M3-selective agent, theoretically offers reduced side effects (cardiac, cognitive) but clinical data do not consistently support superior tolerability or efficacy.

Related Experiment Videos

  • While darifenacin shows a documented lack of cognitive side effects, definitive comparative data against other modern anticholinergics are pending.

    • Impact:

    • Understanding muscarinic receptor subtypes is crucial for developing targeted OAB therapies with improved side effect profiles.
    • Clinical data are needed to confirm the real-world advantages of M3-selective anticholinergics in OAB management.
    • This research informs the selection of anticholinergic treatments for overactive bladder, balancing efficacy with patient-reported outcomes and tolerability.